BioCentury
ARTICLE | Financial News

Zymeworks raises $61.5M, invests in Kairos

January 9, 2016 2:22 AM UTC

Antibody play Zymeworks Inc. (Vancouver, B.C.) raised US$61.5 million in a round co-led by new investors BDC Capital and Lumira Capital. Existing investors Eli Lilly and Co. (NYSE:LLY), Celgene Corp. (NASDAQ:CELG), CTI Life Sciences Fund, and Fonds de solidarite FTQ also participated in the round, along with new investors that include Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus.

Zymeworks described the funding as a series A mezzanine round and said it includes preferred shares. The company has raised at least $43 million in five other financings that all involved common shares. Zymeworks also has raised non-dilutive cash through four deals, including partnerships with Lilly and Celgene. Zymeworks has three antibody platform technologies, including its Azymetric platform for bispecific antibodies. ...